Clinical Trials
8 trialsNCT05064358 2026-05-05
DREAMM 14
GlaxoSmithKline
Phase 2 Completed
NCT04617925 2025-09-05
EMN27
European Myeloma Network B.V.
Phase 2 Completed
NCT03828292 2025-08-19
An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments
GlaxoSmithKline
Phase 1 Completed
NCT04177823 2025-03-20
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
GlaxoSmithKline
Phase 1 Completed
NCT03544281 2025-03-18
DREAMM 6
GlaxoSmithKline
Phase 1/2 Completed
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT03848845 2024-04-09
DREAMM 4
GlaxoSmithKline
Phase 1/2 Completed
NCT02064387 2020-08-11
Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916
GlaxoSmithKline
Phase 1 Completed